U.S. Stock Market Midday Update
CEL-SCI fell 10.47%, with increased trading volume. Based on recent key news:
<ol>
<li>
On May 18, CEL-SCI's stock price dropped significantly by 10.47%, with a notable increase in trading volume. This fluctuation may be related to internal shareholder trading activities. According to SEC filings, director and CEO Geert R Kersten purchased 300,000 shares on May 14 for $360,000, indicating confidence in the company's future, but the market reacted poorly, leading to the stock price decline.
</li>
<li>
On May 18, CEL-SCI released a news brief indicating that the company published relevant information through Business Wire. Although the content was generated by AI and does not constitute investment advice, the market's reaction to the information may have affected the stock price.
</li>
<li>
On May 18, market attention towards CEL-SCI increased, especially in the Hong Kong and U.S. markets. Although there was no mention of specific dynamics in the A-share market, overall market sentiment may have impacted the stock price. Market sentiment is volatile, and industry dynamics should be monitored.
</li>
</ol>
Top Stocks by Trading Volume in the Industry
AbbVie rose 2.16%. Based on recent key news:
<ol>
<li>
On May 19, Belgian biopharmaceutical company UCB announced Phase III study data for its IL-17A/IL-17F inhibitor Bimzelx, showing it outperformed AbbVie's Skyrizi in treating psoriatic arthritis. This result may impact AbbVie's market competitiveness.
</li>
<li>
On May 18, MarketBeat noted that although AbbVie received a moderate buy rating from analysts, five other stocks were considered better investment choices, which may affect investor confidence in AbbVie.
</li>
<li>
On May 17, MarketBeat analysts did not include AbbVie in their recommended list, despite its moderate buy rating, which may lead to market concerns about its future performance. The pharmaceutical industry is becoming increasingly competitive, and market dynamics should be monitored.
</li>
</ol>
Regeneron Pharmaceuticals rose 0.13%. Based on recent key news:
<ol>
<li>
On May 18, Regeneron Pharmaceuticals announced that its key investigational drug fianlimab in combination with Libtayo failed to meet its primary endpoint in a Phase III clinical trial, causing the stock price to plummet over 11% in pre-market trading. Several investment banks subsequently downgraded their ratings and target prices. Leerink downgraded its rating from &#34;Outperform&#34; to &#34;Market Perform,&#34; with the target price significantly reduced from $792 to $641. Analysts from BMO Capital Markets and Evercore ISI also removed fianlimab from their financial models after evaluation.
</li>
<li>
On May 18, Regeneron Pharmaceuticals announced a strategic collaboration agreement with Parabilis Medicines to advance the application of the novel antibody-Helicon™ conjugate in multiple therapeutic areas
According to the agreement, Parabilis will receive $125 million from Regeneron, as well as up to $2.2 billion in potential milestone payments and tiered royalties.
</li>
</ol>
On May 18, JP Morgan lowered the target price for Regeneron Pharmaceuticals from $950 to $850, reflecting the market's reaction to its recent clinical trial failures. The recent clinical trial failures have affected market confidence, leading to significant stock price fluctuations.
Amgen rose 2.14%. Based on recent news:
<ol>
<li>
On May 18, U.S. President Trump announced a drug discount policy that will increase the availability of 600 generic drugs. This policy is expected to reduce patients' drug costs, increase drug demand, and drive up Amgen's stock price.
</li>
<li>
On May 18, analyst ratings showed that Amgen currently has a hold rating, but five other stocks are considered better investment choices. This rating may exert some pressure on Amgen's stock price, but the overall impact is limited.
</li>
<li>
On May 18, market attention to kidney disease, bone health, and cardiovascular disease has increased. As a major company in these related fields, Amgen benefits from the growing demand for treatments for these diseases, driving up its stock price. The market demand for drugs is increasing, and the policy is favorable.
</li>
</ol>
Stocks ranked among the top in industry market capitalization
Gilead Sciences rose 1.18%. Based on recent key news:
<ol>
<li>
On May 19, Gilead Sciences reached a collaboration agreement with Compugen worth up to $848 million, involving clinical development and commercialization for solid tumors. This news boosted market confidence and drove up the stock price.
</li>
<li>
On May 19, Gilead Sciences' Chief Financial Officer Andrew D. Dickinson sold 3,000 shares of common stock at a price of $132.27 per share. Although this move may raise concerns among some investors, the overall market reaction has been relatively stable.
</li>
<li>
On May 19, Gilead Sciences' multiple investments and collaborations in the oncology field have not yielded significant returns as expected, leading to continued sluggish revenue in its oncology segment. However, the company is still actively positioning itself in emerging fields, attempting to achieve breakthroughs through high-potential tracks. The oncology segment is underperforming, but capital flows are positive
</li>
</ol>

CEL-SCI fell 10.47%; AbbVie rose 2.16%, with a transaction volume of USD 668 million; Regeneron Pharmaceuticals rose 0.13%, with a transaction volume of USD 579 million; Amgen rose 2.14%, with a transaction volume of USD 439 million; Gilead Sciences rose 1.18%, with a market capitalization of USD 162.9 billion

Price Alert

CEL-SCI

U.S. stock market update: CEL-SCI's stock price fell by 10.47%, and insider trading confidence failed to boost market sentiment